Načítá se...
Pneumothorax following combination chemotherapy with bevacizumab: A case report and review of the literature
Bevacizumab (BV) is a humanized monoclonal antibody that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF). The addition of BV to combination chemotherapy has been shown to improve the outcomes in several malignancies, including colorectal carcinoma (CRC). However, the use...
Uloženo v:
| Vydáno v: | Mol Clin Oncol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
D.A. Spandidos
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6587012/ https://ncbi.nlm.nih.gov/pubmed/31281652 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2019.1868 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|